This timely volume addresses the areas of pathophysiology and therapy of
pulmonary hypertension, which have seen exciting developments over the
past decade. The discoveries of endothelin overexpression as well as
prostacyclin and nitric oxide deficiency in association with pulmonary
hypertension have led to important therapeutic insights. In addition,
the identification of genes associated with pulmonary hypertension has
just begun to open the door to new pathophysiologic insights. The new
therapies have led to significant improvements in patient function,
quality of life and survival. In this book, expert authors describe
these new therapies. It will be of interest not only to cardiologists,
pulmonary specialists and rheumatologists, but also many nurses and
pharmacotherapists are becoming increasingly involved in the therapy of
patients with pulmonary hypertension.